STUDI PENGGUNAAN PROPRANOLOL PADA PASIEN SIROSIS HEPATIS DENGAN HIPERTENSI PORTAL (Penelitian di Rumah Sakit Umum Daerah Sidoarjo)
Daftar Isi:
- Background : Liver cirrhosis is the final stage of chronic liver disease that causes fibrosis so that a decrease in function and changes in the shape and structure of the liver. Portal hypertension is an important pathophysiology of cirrhosis of the liver, which can cause an increased risk of death in patients resulting in very detrimental complications originating from portal blood flow obstruction such as cirrhosis or blockage of blood vessels. Non-selective groups of β-blockers such as propranolol can reduce portal pressure by reducing portal venous flow through two mechanisms namely decreased cardiac output and decreased splanchnic blood flow. Objective : To determine the pattern of use of propranolol drugs in hepatic cirrhosis patients with portal hypertension in Sidoarjo Hospital. Methods : Observational descriptively in patients with liver cirrhosis with portal hypertension from 01 January to 31 December 2018 Results & Conclusions : The pattern of using single therapy as many as 8 patients (21.6%), combination therapy of two drugs as many as 19 patients (51.4%), and combination therapy of three drugs as many as 10 patients (27%), namely: The most single use of therapy is propranolol ( 3 × 10 mg) PO in 3 patients (37.5%). The most use of combination drug therapy is Propranolol (1 × 10 mg) PO + Octreotid (3 × 100 mcg / 5 ml) IV in 2 patients (10.5%), Furosemide (1 × 20 mg) IV + Propranolol (1 × 10 mg) PO of 2 patients (10.5%), Furosemide (2 × 20 mg) IV + Propranolol (3 × 10 mg) PO of 2 patients (10.5%), Furosemide (3 × 20 mg) IV + Propranolol (2 × 10 mg) PO in 2 patients (10.5%), Furosemide (2 × 20 mg) IV + Propranolol (3 × 20 mg) PO in 2 patients (10.5%). The most use of triple drug combination therapy is Furosemide (1 × 20 mg) IV + Propranolol (2 × 10 mg) PO + Spironolactone (2 × 25 mg) PO in 2 patients (20%), Furosemide (2 × 20 mg) IV + Propranolol (2 × 20 mg) PO + Spironolactone (2 × 100 mg) PO in 2 patients (20%). The switching patterns of therapy (switching) there are 10 patterns.